While plasma FFA levels were not different among the groups (Fig. 1C), CDN1163 significantly decreased fasting plasma insulin levels (Fig. 1G) and restored glucose tolerance (Fig. 1I–K) and homeostatic model assessment for insulin resistance score (Fig. 1H) to control levels. This evidence concerns the gene INS and Insulin resistance.